Home >> Tag Archives: Aspira Labs—

Tag Archives: Aspira Labs—

Ovarian cancer risk test covered in Va., Md., DC

Oct. 10, 2016—Aspira Labs announced a major contract agreement with CareFirst BlueCross BlueShield for their FDA-cleared ovarian cancer risk assessment test, Ova1. CareFirst serves more than three million patients throughout Virginia, Maryland, and Washington, DC. It is the fourth managed care contract for the test announced in recent months Aspira Labs. “Days and weeks matter with ovarian cancer,” Valerie Palmieri, ...

Read More »